IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.674
EU - Europa 857
AS - Asia 671
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
OC - Oceania 1
Totale 6.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.664
SG - Singapore 300
IT - Italia 271
CN - Cina 184
UA - Ucraina 167
DE - Germania 118
IE - Irlanda 77
IN - India 70
VN - Vietnam 64
SE - Svezia 40
FI - Finlandia 32
TR - Turchia 31
CZ - Repubblica Ceca 28
GB - Regno Unito 27
BE - Belgio 25
CH - Svizzera 15
RO - Romania 13
IR - Iran 10
NL - Olanda 10
CA - Canada 9
RU - Federazione Russa 7
FR - Francia 6
JP - Giappone 6
PL - Polonia 6
AT - Austria 5
TG - Togo 4
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
BG - Bulgaria 2
BR - Brasile 2
ES - Italia 2
HK - Hong Kong 2
AL - Albania 1
AU - Australia 1
CM - Camerun 1
CO - Colombia 1
IL - Israele 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
Totale 6.218
Salva come PNG Salva come JPEG
Città #
Fairfield 716
Ashburn 489
Chandler 446
Woodbridge 346
Seattle 300
Singapore 266
Houston 262
Wilmington 241
Cambridge 227
Ann Arbor 207
Boardman 145
Dearborn 115
Jacksonville 98
Princeton 76
Beijing 72
Dublin 72
Dong Ket 64
Udine 51
New York 47
San Diego 39
Washington 34
Izmir 27
Martignacco 26
Redmond 26
Brno 25
Ogden 24
Brussels 22
Dallas 22
Des Moines 21
Los Angeles 20
Munich 20
Zurich 15
Phoenix 13
Falls Church 12
Nanjing 12
Norwalk 12
Hyderabad 11
Milan 11
Leawood 10
Naples 10
Trieste 10
Arezzo 9
Santa Clara 9
Timisoara 9
Hefei 8
Augusta 7
Helsinki 7
Jinan 7
Guangzhou 6
Rome 6
Warsaw 6
Codroipo 5
Cordenons 5
Kunming 5
London 5
Scafati 5
Shanghai 5
Simi Valley 5
Ardabil 4
Bovisio-Masciago 4
Edinburgh 4
Frankfurt am Main 4
Jiaxing 4
Lappeenranta 4
Lomé 4
Menlo Park 4
Nanchang 4
Redwood City 4
Shenzhen 4
Tokyo 4
Zoppola 4
Cairo 3
Caserta 3
Fuzhou 3
Genoa 3
Grafing 3
Hebei 3
Montréal 3
Münster 3
Nutley 3
Paris 3
Porcia 3
San Mateo 3
Tallinn 3
Toronto 3
Treviso 3
Wuhan 3
Bologna 2
Castelfranco Veneto 2
Cavaso del Tomba 2
Chengdu 2
Cincinnati 2
Clifton 2
Como 2
Curno 2
Fairborn 2
Fremont 2
Hangzhou 2
Hong Kong 2
Innsbruck 2
Totale 4.897
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 176
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 140
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 137
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 133
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 132
Pattern of metastasis and outcome in patients with breast cancer 131
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 124
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 123
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 118
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 117
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 116
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 113
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 111
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 111
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 110
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 109
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 104
Do platinum salts fit all triple negative breast cancers? 103
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 101
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 100
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 100
Determinants of Last-line Treatment in Metastatic Breast Cancer 99
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 97
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 94
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 94
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 94
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 93
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 93
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 92
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 92
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 92
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 91
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 91
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 89
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 86
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 85
null 84
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 83
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 82
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 81
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 80
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 79
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 78
Risk factors and survival outcomes in patients with brain metastases from breast cancer 77
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 73
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 72
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 70
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 68
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 67
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 64
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 64
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 64
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 57
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 57
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 55
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 55
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 54
Time to surgery after neoadjuvant chemotherapy for early breast cancer 53
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 51
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 50
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 50
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 49
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 46
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 45
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 43
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 42
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 40
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 37
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 36
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 36
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 35
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer 34
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 32
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 30
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 29
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 27
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 27
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 25
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 24
Landscape of circulating tumour DNA in metastatic breast cancer 23
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools 22
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 21
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 20
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies 19
The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives 18
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 18
The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer 17
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study 17
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 17
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 16
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 16
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 13
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 10
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer 10
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis 10
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 10
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 9
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 9
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects 9
Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II 9
Totale 6.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.831
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.831
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.247 0 0 0 0 140 216 188 176 206 173 89 59
2020/20211.306 52 131 91 229 114 72 85 143 81 69 108 131
2021/2022753 88 69 15 14 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/2025639 130 158 97 110 144 0 0 0 0 0 0 0
Totale 6.607